![img-0.jpeg](img-0.jpeg)

Figure 1 - Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth in vivo. (a) Subconfluent cultures of PAE/PDGFR $\beta$ cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels). Alternatively, PAE/PDGFR $\beta$ cells were incubated for 5 min at $37^{\circ} \mathrm{C}$ with conditioned medium or increasing amounts of PDGF-BB (right panels). PDGFR $\beta$ phosphorylation was analyzed by PDGFR $\beta$ and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle $(\bullet), 3 \mu \mathrm{M}$ STI571 $(\bullet), 1$ $\mu \mathrm{M}$ PTK787 $(\boldsymbol{\Delta})$ or $3 \mu \mathrm{M}$ STI571 and $1 \mu \mathrm{M}$ PTK787 $(\bullet)$. B16/mock (c) or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57Bl6/J mice. When the tumor volume reached $20 \mathrm{~mm}^{3}$, mice received either p.o. gavage of vehicle $(\bullet), 100 \mathrm{mg} / \mathrm{kg} /$ day STI571 $(\bullet), 25 \mathrm{mg} / \mathrm{kg} /$ day PTK787 $(\boldsymbol{\Delta})$ or $100 \mathrm{mg} / \mathrm{kg} /$ day STI571 and $25 \mathrm{mg} / \mathrm{kg} /$ day PTK787 ( $\bigcirc$ ). Treatment was given for 13 days for mice bearing B16/mock tumors (c) and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by post hoc analysis applying the Duncan adjustment. Significance is shown for the last day of treatment: ${ }^{*}, p<0.05$ compared to vehicle treatment; $\S, p<0.05$ compared to PTK787 treatment; 8, $p<0.05$ compared to STI571 treatment. (e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571 ( $25 \mathrm{mg} / 100 \mathrm{mg} / \mathrm{kg} /$ day; lanes 4 and 5), PTK787 ( $25 \mathrm{mg} / \mathrm{kg} /$ day, lanes 6 and 7), STI571 ( $100 \mathrm{mg} / \mathrm{kg} /$ day, lanes 8 and 9) or STI571 ( $200 \mathrm{mg} / \mathrm{kg} /$ day, lanes 10 and 11). PDGFR $\beta$ was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFR $\beta$ and phospho-tyrosine ( pTyr ) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1). The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFR $\beta$ band were compared to the first vehicle-treated tumor to obtain the relative receptor phosphorylation.

## Results

In vitro characterization of a B16F10 melanoma clone which produces PDGF-BB

A B16 melanoma cell line producing PDGF-BB (B16/PDGFBB) was previously established. ${ }^{20}$ This cell line was used to isolate a clone with robust PDGF-BB production that was selected for further experiments. As shown in Figure $1 a$ (left panels), conditioned medium from the selected B16/PDGF-BB clone, but not from a mock-transfected clone (B16/mock), induced strong PDGFR $\beta$ phosphorylation in porcine aortic endothelial cells
transfected with the PDGFR $\beta$ (PAE/PDGFR $\beta$ ), indicating production of a large amount of PDGF-BB. The amount of PDGFBB released into the conditioned medium was estimated by incubating PAE/PDGFR $\beta$ cells with either conditioned medium or increasing amounts of PDGF-BB. After 2 days, the B16/PDGFBB cells had released an amount of PDGF into the medium that was in excess of $0.5 \mathrm{ng} / \mathrm{ml}$ PDGF-BB (Fig. $1 a$, right panels). It should be noted that PDGF-BB sticks to both cells and plastic, so this amount is likely to represent underestimation of the production of PDGF-BB.